GSK Shares Fall 7% After Shingrix Sales Disappoint
GSK reported lower-than-expected sales for its bestselling shingles vaccine, Shingrix, mainly due to weakness in China. Shares fell 7% in European midday trading Wednesday.
By Adria CalatayudGSK shares fell after the U.K. drugmaker reported lower-than-expected sales for its shingles vaccine Shingrix, the company's bestselling product, mainly due to weakness in China.Shares in GSK were down 7% in European midday trading Wednesday, wiping out gains earlier in the year…